Samantha Jandl

Samantha is an associate in the firm’s Complex Litigation & Dispute Resolution practice and is a member of the firm’s Healthcare Disputes & Investigations and Government Investigations & Enforcement groups. She focuses on representing healthcare and life sciences companies and individuals in complex commercial litigation and government and internal investigations.

Samantha also maintains an active pro bono practice representing clients in matters related to reproductive healthcare and gender affirming care, and representing survivors of domestic violence and sexual assault.

While attending law school, Samantha was a summer associate at Goodwin in 2021 and a law clerk at Goodwin during the 2021-2022 school year. Samantha was a member of the Editorial Board of the Northwestern Journal of Technology and Intellectual Property. She also served as the President of Northwestern Law’s High Tech Law Society, the Director of Professional Development for Northwestern Law’s Women’s Leadership Coalition, and the Vice President of Advocacy for Northwestern Law’s chapter of If/When/How: Lawyering for Reproductive Justice.

Prior to law school, Samantha worked as a Senior Analyst with Analysis Group, Inc. in both Boston and London. At Analysis Group, Samantha supported expert witness testimony in financial litigation through data-driven analysis and insights, achieving trial wins and advantageous settlements on behalf of leading financial institutions and Fortune 500 companies.

• Co-Author, “How Medicaid Cuts Could Reshape the Business of Health,” Forces of Law 2026, December 10, 2025
• Co-Author, “DOJ-HHS Announces False Claims Act Working Group, Emphasizes Healthcare Fraud Enforcement Priorities,” Goodwin Client Alert, July 21, 2025
• Co-Author, “Changes to Birthright Citizenship and the Impact on Fertility and Assisted Reproduction Clinics,” Goodwin Client Alert, July 3, 2025
• Co-Author, “HHS-OCR Publishes Final HIPAA Privacy Rule Expanding Reproductive Health Care Privacy and Further Supporting Patient Confidentiality,” Client Alert, June 17, 2024
• Co-Author, “A Tale of Two Lawsuits: Federal Court in Texas Suspends FDA Approval of Medication Abortion Drug Mifepristone Nationwide, While Federal Court in Washington Orders FDA to Not Alter Availability of Mifepristone in 17 States and D.C.,” Client Alert, April 11, 2023
• Co-Author, “HHS to Create New Potential Medicare Pricing Models for Cell and Gene Therapy, Drugs Subject to Accelerated FDA Approval, and “High-Value” Generics,” Client Alert, March 14, 2023